Tweet
<img alt="" height="1" width="1" />
GenVec shares plunge after cancer drug trial discontinued
Reuters
(Reuters) - Shares of GenVec Inc (GNVC.O) fell as much as 75 percent Tuesday, a day after the company said it was discontinuing a trial for its lead experimental gene therapy drug for pancreatic cancer. Interim results from a trial showed TNFerade was ...
GenVec dives after ending cancer drug trialForbes
GenVec shares crater on failed drug studyMarketWatch
GenVec stock plummets as biotech stops cancer drug trialBusiness Gazette
Washington Business Journal -Learning Markets -The Market Financial
all 72 news articles »
More...